Modality
Gene Therapy
MOA
FcRni
Target
TIM-3
Pathway
Complement
Heart FailureCrohn's
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
Phase 2Current
NCT07832847
978 pts·Crohn's
2017-02→TBD·Completed
978 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07832847 | Phase 2/3 | Crohn's | Completed | 978 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Rimanesiran | Merus | Phase 1 | TIM-3 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| Fixabrutinib | Verve | Phase 1 | RET | |
| Niratinib | Alumis | NDA/BLA | TIM-3 |